Amgen Tops Estimates With Q3 Revenue of $10.4 Billion and Adjusted EPS of $6.45
Amgen gave full-year 2026 revenue guidance of $38.9 billion to $39.7 billion and non-GAAP EPS guidance of $22.90 to $23.70.
Amgen AMGN
Amgen Inc · Nasdaq · Biological Products, (No Diagnostic Substances)
$461.26-0.90%close on Nov. 3, 2026 · volume 2.3M · Yahoo Finance
Price, last 51 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 13, 2026 | Rachna Khosla SVP, Business Development | Sold | 1,252 | $416.43 | $521,365 |
| Aug. 11, 2026 | Rachna Khosla SVP, Business Development | Sold | 2,000 | $412.57 | $825,134 |
| Aug. 6, 2026 | Derek Miller SVP, Human Resources | Sold | 3,890 | $402.54 | $1.57 million |
| Aug. 6, 2026 | Nancy A. Grygiel SVP & CCO | Sold | 2,970 | $402.16 | $1.19 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 12 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedAmgen Q3 2026 non-GAAP EPS of $6.45 beats $5.78 consensus on $10.4 billion revenue; full-year non-GAAP EPS guidance $22.90 to $23.70 brackets $23.02 consensus
Departure/appointment of directors or officers
AI summary, unreviewedAmgen Appoints David W. Gibbs, Former Yum! Brands CEO, to Board of Directors